HCV Previous Non-Responders Have Twice the Viral Clearance with TMC435
Medivir Announces Final Results from TMC435 Phase IIb ASPIRE (C206) Study
Published: Wednesday, Nov. 2, 2011
TMC435-Based Therapy Significantly Improved Viral Cure Rates in Patients Who Failed Prior Treatment for Hepatitis C
– ASPIRE: All TMC435 subgroups achieved substantially higher viral cure rates (SVR24) compared with control group (pegylated interferon and ribavirin alone): 85% vs. 37% in prior relapsers, 75% vs. 9% in prior partial responders and 51% vs. 19% in prior null responders –
– Once daily TMC435 was generally safe and well tolerated at all doses and treatment durations –
Medivir AB (OMX: MVIR), a research-based speciality pharmaceutical company focused on infectious diseases, today announces final results from the ASPIRE study. This phase IIb study evaluated TMC435 once daily in addition to pegylated interferon (PegIFN) and ribavirin (RBV) in patients with genotype-1 chronic hepatitis C whose prior treatment with PegIFN and RBV was unsuccessful either because they relapsed, had a partial response or had a null response.
Data from the ASPIRE study showed that patients in each of these subgroups who were treated with TMC435-based combination therapy achieved superior rates of sustained virologic response (viral cure) compared with those retreated with PegIFN and RBV alone.
Continue reading this entire article:
No Interferon in Phase 3 Trials of Hep C Drug PSI-7977
Johns Hopkins University - Upcoming Hep C Clinical Studies & Enrollments